Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial

Patients with ulcerative colitis (UC) regard rapid onset of action among the most important aspects of their treatment. We used the partial Mayo Clinic Score (pMCS) and component patient-reported subscores to assess the rapidity and sustainability of response to filgotinib, a once-daily, oral Janus...

Descripción completa

Detalles Bibliográficos
Autores principales: Danese, Silvio, Ferrante, Marc, Feagan, Brian G., Peyrin-Biroulet, Laurent, Hibi, Toshifumi, Sandborn, William J., Schreiber, Stefan, Ritter, Timothy, Loftus, Edward V., Rogler, Gerhard, Oortwijn, Alessandra, Yun, Chohee, Le Brun, Franck-Olivier, Dinoso, Jason, Hsieh, Jeremy, Vermeire, Séverine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810009/
https://www.ncbi.nlm.nih.gov/pubmed/36113491
http://dx.doi.org/10.14309/ajg.0000000000001979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810009/
https://www.ncbi.nlm.nih.gov/pubmed/36113491
http://dx.doi.org/10.14309/ajg.0000000000001979

Ejemplares similares